Biogen’s chances of getting an FDA approval for its tofersen drug candidate for amyotrophic lateral sclerosis (ALS) patients who have mutations in the SOD1 gene have been
Gene-editing specialist Sangamo Therapeutics has lost not one but two sizeable partnerships with larger biopharma companies, with Novartis and Biogen both walking away fro
In a big boost to Eisai and partner Biogen, the US Department of Veterans Affairs has agreed to cover their new amyloid-busting Alzheimer’s disease therapy Leqembi, becomi
Eisai and partner Biogen have edged closer to a full FDA approval of their Alzheimer’s disease therapy Leqembi, after the US regulator set a 6th July date for their market
The US Centers for Medicare and Medicaid Services (CMS) has rejected broader coverage of new amyloid-targeting Alzheimer’s disease treatments, a decision branded “pernicio
Eisai didn't reveal sales of its new Alzheimer's disease therapy Leqembi in its third-quarter update, but said the launch was running "ahead of expectations" since the dru
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t